News
Alpha-1 Foundation, AARC Cooperate on Landmark PFT Study; 5,000 COPD Patients will be Tested for Alpha-1
DENVER, CO – Some 5,000 COPD patients will be tested to determine the prevalence of Alpha-1 Antitrypsin Deficiency (Alpha-1) in a study marking a major cooperative effort between the Alpha-1 Foundation and the American Association for Respiratory Care (AARC).
The principal investigator for the study is Robert A. Sandhaus, MD, PhD, of the Division of Pulmonary Medicine, National Jewish Medical and Research Center in Denver. Sandhaus is also the Clinical Director of the Alpha-1 Foundation.
According to Sandhaus, “If the current literature is correct, the study should identify about 50 to 100 individuals who are unaware they have COPD due to Alpha-1. In addition, the study should identify about 300 people who are carrying a single abnormal Alpha-1 gene and all will be counseled about the potential risk to their children and family members.”
